A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients

類似資料

• Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
  著者:: Kalra, Philip A.
  出版事項: (2011)
• Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
  著者:: Kalra, Philip A, 等
  出版事項: (2016)
• Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience
  著者:: Jesus-Silva, Jorge A., 等
  出版事項: (2020)
• Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
  著者:: Bhandari, Sunil, 等
  出版事項: (2020)
• A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
  著者:: Kalra, Philip A., 等
  出版事項: (2016)